Title: Prevalence of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Pseudomonas Aeruginosa in Different Clinical Samples in Tertiary Care Center
Authors: Arundhati Jamatia, Debesh Debbarma, Anik Bhattacharjee, Debashis Roy, Abhijit Sarkar, Banti Das
DOI: https://dx.doi.org/10.18535/jmscr/v5i6.215
Abstract
Antibiotic resistance is one of the alarming issues, affecting human health P. aeruginosa is a prototype of “multidrug-resistant pathogen” and is recognized for its ubiquitous distribution, advanced antibiotic resistance mechanisms, and nosocomial infections.. The organism is classified into various phenotypes based on the drug resistance pattern, namely, drug-resistant (DR), multi-DR (MDR), extensively DR (XDR), and pan-DR (PDR).
Methods: This cross sectional study was conducted in Microbiology Department of Agartala Govt Medical college under GBP hospital , from 1st January 2016 to31st December 2016. Clinical specimens were collected from different clinical departments of GBP hospital. Clinical isolates were identified by standard and specific microbiological methods. The antibiotic susceptibility pattern was determined by Kirby Bauer Disc diffusion method. Clinical and Laboratory Standards Institute (CLSI) guidelines were used to determine the results.
Results: The frequency of MDR P. aeruginosa isolated from different clinical specimens was found to be43.43%. Antibiotic resistance studies revealed that 50.51% of P. aeruginosa isolates were DR, and 6.06% were XDR phenotype. None of the strains showed PDR phenotype. Amikacin was found to be the most effective antibiotic, followed by Carbapenem group of drugs .
Conclusion: Our data revealed a high prevalence of DR phenotypes of P. aeruginosa in the total isolate of P aeruginosa. There is an urgent need to resolve the issue by taking some preventive measures. Combined efforts of health care professionals and researchers are required to educate people about the proper use of antibiotics and other infection control measures.
Keywords: Drug resistance, multidrug-resistant phenotype, Extensively Drug-resistant, and Pandrug-resistant of Pseudomonas aeruginosa.
References
1. Bhatia R, Narain JP. The growing challenges of antimicrobial resistance in the South-Asia Region - Are we losing the Battle. Indian J Med Res. 2010;132(5):482–486.
2. Prakash Ravichandra H, Belodu Rashmi, Karangate Neena, Sonth Suresh, Anitha MR, Vijayanath V. Antimicrobial susceptibility pattern of Pseudomonas aeruginosa strains isolated from clinical sources. Journal of Pharmaceutical and Biomedical Research. 2012;14(05)
3. Strateva T, Yordanov D. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J Med Microbial. 2009;58(Pt 9):1133–48. [PubMed]
4. Mohanasundaram KM. The antimicrobial resistance pattern in the clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital: 2008-2010(a 3 year study) Journal of Clinical and Diagnostic Research. 2011;Vol-5(3):491–94.
5. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–82. [PMC free article] [PubMed]
6. Magiorakos AP. Multidrug Resistant (MDR), Extensively Drug Resistant (XDR) and Pandrug-1 Resistant (PDR) Bacteria in Healthcare Settings. Expert Proposal for a Standardized International Terminology. 2011
7. Chaudhary U, Aggarwal R. Extended spectrum-lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J Med Microbiol. 2004;22:75–80. [PubMed]
8. Thuong M, Arvaniti K, Ruimy R, de la Salmonière P, Scanvic-Hameg A, Lucet JC, et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect. 2003;53:274–82. [PubMed]
9. Shalini S, Kranthi K, Gopalkrishna Bhat K. Microbiological profile of infections in ICU. J Clin Diagn Res. 2010;4:3109–12.
10. Mukhopadhyay C, Bhargava A, Ayyagari A. Role of mechanical ventilation and development of multidrug resistant organisms in hospital acquired pneumonia. Indian J Med Res. 2003;118:229–35. [PubMed]
11. Siti Nur Atiquah Idris et al. Antimicrobial susceptibility pattern and distribution of EXO U and EXO S in clinical isolates of pseudomonas aeruginosa at a Malaysian hospital
12. Paranjothi S, Dheepa R. screening for multidrug resistance bacteria Pseudomonas aeruginosa in hospitalized patients in Hosur,Krishnagiri(dt) International Journal of Pharma and Biosciences. 2010;Vol.1(Issue-3)
13. Senthamarai S.,
1 Suneel Kumar Reddy A.,2 Sivasankari S et al. Resistance Pattern of Pseudomonas aeruginosa in a Tertiary Care Hospital of Kanchipuram, Tamilnadu, India. J Clin Diagn Res. 2014 May; 8(5):
14. Elizabeth BH, Vincent HT. Impact of multi-drug resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(4):441–451.
15. PfeiferY , CullikA , WitteW ResistancetocephalosporinsandcarbapenemsinGram-negativebacterialpathogens. IntJMedMicrobiol. 2010;300(6):371–379. doi:10.1016/j.ijmm.2010.04.005.
16. Wang LJ, Sun Y, Song WL, Zhang ZJ, Liu CF. Changes of drug-resistance of Pseudomonas aeruginosa in pediatric intensive care unit. Zhonghua Er Ke Za Zhi. 2012;50(9):657–663
17. Hamza AU, Iqbal J, Khan K, Shah MA. Invitro, comparative antibacterial susceptibility pattern of third generation cephalosporins against Pseudomonas aeruginosa by using broth dilution method. Asian J Pharmacy Life Sci. 2013;3(3):164–168.
18. Jombo GTA, Jonahi P, Ayeni JA. Multi drug resistant Pseudomonas aeruginosa in contemporary medical practice: Findings from urinary isolates at a Nigerian University teaching hospital. Nigerian J Physiol Sci. 2008;23(1-2):105–109
19. Javiya VA, Ghatak SB, Patel KR, Patel JA. Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India. Indian J Pharmacol. 2008;40:230–4
20. Rodríguez-Martínez JM, Poirel L, Nordmann P. Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(11):4783–4788. doi:10.1128/AAC.00574-09.
21. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, et al. Prevalence, mechanism and susceptibility of multidrug resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:1160–1164
22. Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria–a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci. 2008;15:5–14
23. Meenakumari S, Verma S, Absar A, Chaudhary A. Antimicrobial Susceptibility Pattern of Clinical Isolates of Pseudomonas aeruginosa in an Indian Cardiac Hospital. Int J Engineering Sci Tech. 2011;3(9):7117–7124.
24. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;2:24–28.
25. Gill MM, Usman J, Kaleem F, Hassan A, Khalid A, Anjum R, Fahim Q. Frequency and Antibiogram of Multi-drug Resistant Pseudomonas aeruginosa. J Coll Physicians Surg Pak. 2011;21(9):531–534. doi: 09.2011/JCPSP.531534.
26. Fouzia Khan,1 Adnan Khan,2 and Shahana Urooj Kazmi3. Prevalence and Susceptibility Pattern of Multi Drug Resistant Clinical Isolates of Pseudomonas aeruginosa in Karachi. Pak J Med Sci. 2014 Sep-Oct; 30(5): 951–95